Skip to Content
Merck
CN
  • ERK8 is a negative regulator of O-GalNAc glycosylation and cell migration.

ERK8 is a negative regulator of O-GalNAc glycosylation and cell migration.

eLife (2014-03-13)
Joanne Chia, Keit Min Tham, David James Gill, Emilie Anne Bard-Chapeau, Frederic A Bard
ABSTRACT

ER O-glycosylation can be induced through relocalisation GalNAc-Transferases from the Golgi. This process markedly stimulates cell migration and is constitutively activated in more than 60% of breast carcinomas. How this activation is achieved remains unclear. Here, we screened 948 signalling genes using RNAi and imaging. We identified 12 negative regulators of O-glycosylation that all control GalNAc-T sub-cellular localisation. ERK8, an atypical MAPK with high basal kinase activity, is a strong hit and is partially localised at the Golgi. Its inhibition induces the relocation of GalNAc-Ts, but not of KDEL receptors, revealing the existence of two separate COPI-dependent pathways. ERK8 down-regulation, in turn, activates cell motility. In human breast and lung carcinomas, ERK8 expression is reduced while ER O-glycosylation initiation is hyperactivated. In sum, ERK8 appears as a constitutive brake on GalNAc-T relocalisation, and the loss of its expression could drive cancer aggressivity through increased cell motility. DOI: http://dx.doi.org/10.7554/eLife.01828.001.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ro-31-8220, InSolution, ≥95%, protein kinase inhibitor